9,030
Total Claims
$3.4M
Drug Cost
940
Beneficiaries
$3,669
Cost/Patient
Peer Comparison vs. 6,382 Endocrinology providers
-7%
Cost per patient vs peers
$3,669 vs $3,933 avg
+9%
Brand preference vs peers
55.7% vs 51.2% avg
Brand vs Generic
44% generic
Brand: 4,624 claims · $3.2M
Generic: 3,675 claims · $79K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 374 | $287K |
| Tirzepatide | 190 | $244K |
| Dulaglutide | 186 | $222K |
| Insulin Aspart | 173 | $185K |
| Semaglutide | 160 | $184K |
| Insulin Aspart Prot/Insuln Asp | 115 | $149K |
| Insulin Aspart | 121 | $140K |
| Insulin Degludec | 248 | $140K |
| Sitagliptin Phosphate | 165 | $126K |
| Insulin Degludec | 62 | $96K |
| Teriparatide | 19 | $85K |
| Insulin Lispro Protamin/Lispro | 107 | $79K |
| Insulin Lispro | 81 | $78K |
| Linagliptin | 88 | $68K |
| Insulin Glargine,hum.Rec.Anlog | 114 | $67K |
Prescribing Profile
Patient Profile
72
Avg Age
73%
Female
1.46
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About